// App-Quantinova.ai

: Radiographic progression-free survival (rPFS) and time to radiographic progression (TTrP) as surrogate endpoints in docetaxel-naïve metastatic castrate resistant prostate cancer (mCRPC): A pooled analysis of COU-AA-302 and ACIS.

Researchers

Presenter

  • Soumyajit Roy

Principal Investigators

  • Yilun Sun

  • Daniel Eidelberg Spratt

  • Scott C. Morgan

  • Thomas Kim

  • Julia Malone

  • Christopher J.D. Wallis

  • Amar Upadhyaya Kishan

  • Fred Saad

  • Shawn Malone

Medical Centers

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • University of California, Los Angeles, Los Angeles, CA

  • University Hospitals Cleveland Medical Center / Case Western Reserve University School of Medicine, Cleveland, OH

  • Rush University Medical Center, Chicago, IL

  • University of Montreal, Montreal, QC, Canada

  • The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

  • Case Western Reserve University, Cleveland, OH

  • Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved